Pipeline Programs
CGT Companies Tracked
Manufacturing Facilities
The liver cancer drugs market size was valued at US 3.48 billion in 2025 and is projected to grow to 3.97 billion in 2026. Forecasts suggest it will reach approximately US$ 13.13 billion by 2035, registering a CAGR of 14.2% during the period.
With over 800,000 fatalities per year, liver cancer ranks as the fourth most common cause of death worldwide.
Public health authorities are extremely concerned about liver cancer because clinical cases are rising annually and the disease has a 30%–35% projected 5-year survival rate after diagnosis. The formation of malignant cells in the tissues of the liver is primary liver cancer. When cancer forms in other parts of the body and then is transferred to the liver is not primary liver cancer, instead, it can be considered metastatic cancer. Hepatocellular carcinoma is the most common form of liver cancer (approximately 90%) among others. Hepatoblastoma and intrahepatic carcinoma are some other types of liver cancers that are not very common. The cause of liver cancer is unknown but at times, chronic hepatitis infections can ultimately lead to liver cancer. Rising hepatitis B and hepatitis C can lead to an increased risk of developing liver cancer.
For instance,
Hepatitis B caused around 820000 deaths across the globe mostly due to hepatocellular carcinoma and liver cirrhosis (primary liver cancer). First-line treatment for advanced liver cancer involves a variety of medications and immunotherapy, while second-line treatment consists of chemotherapeutic medications derived from both natural and synthetic sources. First-line treatments include sorafenib and lenvatinib; second-line treatments include regorafenib and ramucirumab. The best course of treatment for liver cancer varies mostly on the stage at which the disease is progressing. Tyrosine kinase inhibitors (TKIs), among other second-line treatments, have been demonstrated in a large population of patients with uHCC, including those who have had immunotherapy, to prolong survival and improve outcomes while maintaining a stable safety profile. Surgical options include hepatectomy and liver transplantation, as well as ablation and radiation therapy.
Central Drug Research Institute, India conducted a collaborative study indicating that preventing this difficult disease may include focusing on the metabolic alterations that occur in cells.
Excess fat is produced in people with type 2 diabetes because their liver is unable to continuously regulate excessive blood sugar levels. Liver cancer is more likely to occur in those with nonalcoholic fatty liver disease.
Nonalcoholic Fatty Liver Disease (NAFLD) can cause irreversible hepatic inflammation and scarring, leading to cirrhosis. Liver damage and an increased risk of liver cancer are caused by type 2 diabetes, which initiates a series of complex health concerns. The risk of liver cancer is two to four times higher in those with type 2 diabetes than in people without diabetes.
Based on the February 2024 update, a readily measurable biophysical characteristic can be used to identify Type 2 diabetics who don't satisfy the existing screening standards but are at elevated risk of liver cancer, according to a Stanford Medicine study.
Study Implications:
Over the past few years, several big players in cancer therapeutics have come into the picture for studying and developing new treatment approaches for liver cancers. Manufacturers are actively performing clinical trials on the combination therapies and developing advanced treatment options.
For instance,
With 90% of all instances ever reported, Hepatocellular Carcinoma (HCC) is the most common basic liver cancer. With a mere 3% 5-year survival rate, HCC ranks third in terms of cancer-related deaths. Patients have experienced clinical improvements in the advanced stages because of systemic therapy, but the prognosis is still quite bad. Novel molecular-targeted medicines have been created and clinically tested in the last few decades, with intriguing outcomes. Still, there is a pressing need for research into new medicines given the poor prognoses and limited advantages from current systemic therapy. Here comes the role of targeted and advanced therapies.
The prognosis is still quite miserable, but systemic therapy is the only ones that show any clinical effect in the latter stages. Therefore, to enhance the clinical results of patients with advanced HCC, new systemic treatment options must be developed. Novel molecular-targeted treatments have been created in the past few decades. More specifically, several small compounds that target Receptor Tyrosine Kinases (RTKs) have been tested in clinical settings.
| Sr. No. | Type of Therapy | Targeted Therapies |
| 1. | Tyrosine Kinase Inhibitors | Sorafenib |
| Lenvatinib | ||
| Cabozantinib | ||
| Regorafenib | ||
| 2. | VEGF Inhibitors | Bevacizumab + Atezolizumab |
| Ramucirumab | ||
| 3. | Other Targeted Agents | Donafenib |
| Nintedanib | ||
| Galunisertib | ||
| Galunisertib + Sorafenib |
Over the past 16 years, the treatment landscape of hepatocellular carcinoma has exhibited a significant transformation due to major advancements in targeted therapy. This growing journey can be attributed to several factors such as:
Patients with advanced HCC can now expect better treatment outcomes and a more optimistic prognosis because of these developments in targeted therapy.
BST02 is Biosyngen’s ( an immune-oncology company) immune therapy product that received the FDA’s Fast Track Development Grant in February 2024 for its clinical development to treat all types of liver cancer. BST02's developer, Biosyngen, is pushing the boundaries of cancer treatment development and approval by using the patient's immune system to fight cancer—a strategy that may even surpass more established TIL medicines. Adoptive immune cell treatment technique includes BST02, a T cell therapy that is based on the patient's own tumor infiltrating lymphocytes growing larger. It has the potential to treat liver cancer in all its forms, giving sufferers fresh hope. Compared to conventional TIL therapies, BST02 has many advantages, such as the capacity to get over geographic restrictions because of its cryopreserved form and the decreased requirement for large interleukin-2 dosages.
The incidence and prevalence of non-infectious diseases have sharply grown in recent decades, despite significant progress in their prevention and control. Liver cancer ranks second in terms of cancer-related deaths and is the sixth most frequent type of cancer in Asia. Approximately 609,596 new cases of liver cancer were reported in Asia in 2020, making up roughly 72.5% of the global liver cancer incidence.
There are regional differences as well; sub-Saharan Africa and East Asia have the greatest rates, although their underlying reasons are distinct. High-income nations have seen a decrease in liver cancer cases as a result of widespread viral hepatitis treatment and vaccination programs. On the other hand, there is a rise in low-income nations, which is frequently related to dangerous injection techniques and viral hepatitis.
For instance,
Countries that are contributing to the growth of the market in North America are the U.S. and Canada. Recent advances in liver cancer treatment include targeted therapy, immunotherapy, and gene therapy, which provide novel hope for improved patient outcomes in liver cancer patients. In liver cancer, medicines like pembrolizumab and nivolumab have shown promise in the management of advanced cases, either as standalone treatments or in combination with various therapies. These modern advances in liver cancer therapy present an important shift in the therapeutic landscape, providing novel hope for patients who may not respond well to outdated treatments or have modern disease, which drives the growth of the market in North America.
U.S. Market Trends
The U.S. liver cancer drugs market is shifting toward newer immune-based combinations and targeted treatments. In 2025, the FDA approved nivolumab with ipilimumab for first-line advanced hepatocellular carcinoma, widening treatment choices. Better biomarker testing can help doctors match patients with suitable drugs. Over the next decade, more clinical trials, faster approvals, combination therapies, and improved access to specialist cancer care should support continued market growth. This can support access.
Canada Market Trends
Canada’s liver cancer drugs market is gaining from stronger cancer care networks and wider use of modern systemic treatments. Hospitals are increasingly focused on therapies that can help patients with advanced disease. Public funding remains important for access. Over the next decade, growth could be supported by earlier diagnosis, broader provincial reimbursement, local clinical trials, and simpler treatment pathways. Partnerships with cancer centers may also improve adoption. Better data helps.
Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The Asia Pacific liver cancer drugs market has strong room to expand because the region carries a heavy disease burden. China, Japan, and Southeast Asian countries are adding modern systemic options. Lower-cost medicines can widen access. During the next decade, stronger screening, hepatitis control, local drug production, and more regional trials could speed treatment adoption, especially outside major cities. Rural outreach matters especially in underserved areas and smaller cities where care remains limited.
China Market Trends
China is becoming a major force in the liver cancer drugs market, supported by a large patient pool and a growing domestic drug industry. Local companies offer targeted medicines and immune therapies, giving doctors more choices. The next decade could bring stronger growth through cheaper local products, wider hospital access, improved screening, and research into treatment combinations. Faster uptake of new therapies should further strengthen demand. Specialist training can help.
India Market Trends
India’s liver cancer drugs market has an important opportunity in improving access to advanced treatment. Many patients still reach hospitals after disease progression, creating a need for affordable systemic therapies. Domestic pharmaceutical companies can help lower treatment costs. Over the next decade, wider hepatitis screening, stronger oncology services, better insurance coverage, and more clinical research could expand treatment use. Improved awareness may also encourage earlier medical visits. Public education helps.
In June 2026, “Controlling liver cancer growth is essential because it directly impacts both survival and liver function,” explains Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Ghassan K. Abou-Alfa, MD, JD, MBA, PhD (hc), who led the study. “By combining dual immunotherapy with TACE, we give patients a better chance of living longer while preserving a healthy, working liver,” Dr. Abou-Alfa says. “For our patients and their families, this translates into real, meaningful time together.”
By Drug Class
By Distribution Channel
By Geography
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
